Printout from Pearl Cohen Zedek Latzer Baratz

News / Jan 09, 2019

Stelexis Therapeutics Closes $43 million

Search By

  News & Publications

Stelexis Therapeutics Closes $43 million Series A to Expand Novel Platform Focused on Cancer Interception

Mark Cohen, Senior Partner and Chair of the Life Science Practice Group represents Stelexis Therapeutics in intellectual property and commercial matters.

For the full article, click HERE 

Read these items